医疗补助支付方身份与初次全髋关节置换术后90天并发症发生率及资源利用增加相关:倾向性评分匹配分析
基于2013年全国再入院数据库,将5,311例医疗补助患者与倾向性评分匹配的5,311例非医疗补助患者比较。医疗补助组总体再入院率28.8% vs 21.0%(RR=1.37),髋部特异性再入院率2.5% vs 1.8%(RR=1.38),平均住院日4.5 vs 3.3天,平均总费用71,110 vs 65,309美元。结论认为医疗补助支付方身份与资源利用增加独立相关。
要点
- 医疗补助患者总体再入院率28.8%,非医疗补助患者21.0%(p<0.001;RR=1.37)。
- 医疗补助患者髋部特异性再入院率2.5%,非医疗补助患者1.8%(p=0.01;RR=1.38)。
- 医疗补助患者平均住院日4.5天、平均总费用71,110美元,均高于非医疗补助患者。
核心结论
- 医疗补助支付方身份与初次全髋关节置换术后资源利用增加独立相关,包括再入院率、住院日和总费用。
- 作者认为,提供者可能缺乏动力治疗术后需要增加资源利用的患者人群。
- 作者认为,纳入医疗补助支付方身份的风险调整模型对于避免该人群就医机会减少以及避免医生和医院受到经济处罚是必要的。
研究设计与样本
- 利用全国再入院数据库(NRD)识别2013年接受全髋关节置换术且支付方为医疗补助或非医疗补助的患者。
- 评估人口统计学数据、14种个体合并症、再入院率、住院日和直接费用。
- 采用基于倾向性评分的匹配模型控制支付方组间基线混杂变量。
- 倾向性评分匹配后使用卡方检验比较两组再入院率,估计相对风险(RR)及95%置信区间(CI)。
- 住院日和总费用比较使用Wilcoxon符号秩检验。
主要发现
- 从2013年NRD中识别5,311例医疗补助和144,814例非医疗补助全髋关节置换术患者。
- 基于可用基线人口统计学为每例患者估计倾向性评分,将5,311例非医疗补助患者按倾向性评分与5,311例医疗补助患者匹配。
- 医疗补助组 vs 非医疗补助组总体再入院率为28.8% vs 21.0%(p<0.001;RR=1.37 [95%CI,1.28至1.46])。
- 医疗补助组 vs 非医疗补助组90天髋部特异性再入院率为2.5% vs 1.8%(p=0.01;RR=1.38 [95%CI,1.07至1.78])。
- 医疗补助组平均住院日大于非医疗补助组,为4.5 vs 3.3天(p<0.0001);平均总费用为71,110 vs 65,309美元(p<0.0001)。
关键数值与推荐
- 证据等级:治疗性III级。
临床怎么用
- 作者认为,纳入医疗补助支付方身份的风险调整模型对于避免该人群就医机会减少以及避免医生和医院受到经济处罚是必要的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Medicaid payer status has been shown to affect risk-adjusted outcomes and resource utilization across multiple medical specialties. The purpose of this study was to examine resource utilization via readmission rates, length of stay, and total cost specific to Medicaid payer status following primary total hip arthroplasty. METHODS: The Nationwide Readmissions Database (NRD) was utilized to identify patients who underwent total hip arthroplasty in 2013 as well as corresponding "Medicaid" or "non-Medicaid" payer status. Demographic data, 14 individual comorbidities, readmission rates, length of stay, and direct cost were evaluated. A propensity-score-based matching model was utilized to control for baseline confounding variables between payer groups. Following propensity-score matching, the chi-square test was used to compare readmission rates between the 2 payer groups. The relative risk (RR) with 95% confidence interval (CI) was estimated to quantify readmission risk. Length of stay and total cost comparisons were evaluated using the Wilcoxon signed-rank test. RESULTS: A total of 5,311 Medicaid and 144,814 non-Medicaid patients managed with total hip arthroplasty were identified from the 2013 NRD. A propensity score was estimated for each patient on the basis of the available baseline demographics, and 5,311 non-Medicaid patients were matched by propensity score to the 5,311 Medicaid patients. Medicaid versus non-Medicaid payer status yielded significant differences in overall readmission rates of 28.8% versus 21.0% (p < 0.001; RR = 1.37 [95% CI, 1.28 to 1.46]) and 90-day hip-specific readmission rates of 2.5% versus 1.8% (p = 0.01; RR = 1.38 [95% CI, 1.07 to 1.78]). Mean length of stay was greater in the Medicaid group than in the non-Medicaid group at 4.5 versus 3.3 days (p < 0.0001), as was the mean total cost at $71,110 versus $65,309 (p < 0.0001). CONCLUSIONS: This study demonstrates that Medicaid payer status is independently associated with increased resource utilization, including readmission rates, length of stay, and total cost following primary total hip arthroplasty. Providers may have a disincentive to treat patient populations who require increased resource utilization following surgery. Risk adjustment models accounting for Medicaid payer status are necessary to avoid decreased access to care for this patient population and to avoid financial penalty for physicians and hospitals alike. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Shau D, Shenvi N, Easley K, et al. Medicaid Payer Status Is Associated with Increased 90-Day Morbidity and Resource Utilization Following Primary Total Hip Arthroplasty: A Propensity-Score-Matched Analysis. J Bone Joint Surg Am. 2018. PMID: 30516627. doi:10.2106/JBJS.17.00834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。